Menu

Sleep Circuit

A web of cell types in one of the brain’s chief wake centers keeps animals up—but also puts them to sleep.

Mar 1, 2016
Karen Zusi

INTERWEBS: Activating glutamatergic (GLU) neurons optogenetically excites all other labeled cells types in the basal forebrain of a mouse (1). When cholinergic (CHO) neurons are turned on, they inhibit GLU neurons and excite a subtype of GABAergic neurons containing parvalbumin (PV+). They also excite and inhibit somatostatin-containing (SOM+) GABAergic neurons (2). SOM+ neurons, the only cell type less active during REM sleep and waking, inhibit other neuron types (3). PV+ neurons have minimal or no effects on the other cell types (not shown).© KIMBERLY BATTISTAThe paper
M. Xu et al., “Basal forebrain circuit for sleep-wake control,” Nature Neuroscience, 18:1641-47, 2015.

Early studies attempting to untangle the neurological basis of sleep typically removed or injured part of an animal’s brain to measure the effects. The results implicated a region called the basal forebrain in inducing sleep, yet some studies indicated that it was important for arousal. “The impression is that maybe in that region there’s a mixture of mechanisms,” says Yang Dan, a neurobiologist at the University of California, Berkeley. “But that’s not a very satisfactory answer.”

Dan sought to identify which cells in the basal forebrain promote which brain state. The region contains three main types of neurons: cholinergic, glutamatergic, and GABAergic. Dan and her colleagues further classified the GABAergic neurons into those containing somatostatin (SOM+) or parvalbumin (PV+).

The researchers optogenetically activated each of these four cell types in mice to locate them and track their activity. The cholinergic, glutamatergic, and PV+ GABAergic neurons typically fired multiple times per second when the mice were awake or in REM sleep, but less often during non-REM sleep, a sleep stage in which the brain is less aroused overall. In contrast, non-REM sleep was when the SOM+ GABAergic neurons were most active.

Dan’s team then fired a laser pulse to stimulate the different cell types. If the mice were already awake when the laser activated the cholinergic, glutamatergic, or PV+ GABAergic neurons, the animals’ arousal increased further—and if the animals were in non-REM sleep, they woke up. But when the researchers activated the SOM+ GABAergic neurons, the mice were more likely to go to sleep. “To us, that’s the most exciting,” says Dan. “Everywhere in the brain, it’s easy to find neurons that promote wakefulness,” she explains, but very difficult to find neurons that promote sleep.

To map the connections between each cell type, Dan’s team examined slices of the mouse basal forebrain. In each sample, one type of neuron expressed channelrhodopsin-2 and another a fluorescent identifier. By flashing a light onto the brain tissue, the researchers could activate the light-sensitive neurons and track the synaptic inputs, or lack thereof, to those that were fluorescently labeled.

The different neuron types interacted in a complex hierarchy. Activating glutamatergic neurons excited the three other cell types. Cholinergic neurons activated some neurons, but suppressed others, while PV+ GABAergic neurons had little impact on the labeled cells. Activating the SOM+ neurons, on the other hand, inhibited all three types of wake-promoting neurons. “We think that this is one mechanism for how some neurons can promote sleep,” says Dan. “But, of course, it’s not the only mechanism.”

“There’s an important knowledge gap in the neurosciences as far as how these subpopulations individually contribute to the processes of cortical arousal and wakefulness,” says Patrick Fuller, a neurologist at Harvard Medical School. “The system is wide open for additional empirical testing,” he adds. “That’s the next step.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.